^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:RZ-001 (TERT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PRNewswire
    Title:

    Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

    Published date:
    11/10/2023
    Excerpt:
    Rznomics...announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for RZ-001, for the treatment of patients with Glioblastoma (GBM).